Teva gains shelved Pfizer migraine mAb in $200mm Labrys buy
Teva Pharmaceutical Industries Ltd. paid $200mm up front for Labrys Biologics Inc., a private start-up focused on the treatment of migraine. Teva may also spend up to $625mm in earn-outs based on pre-launch milestones.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.